Adverum Biotechnologies, Inc.

  • Health Care
  • Biotechnology: Biological Products (No Diagnostic Substances)
  • www.adverum.com
  • Moat Score
  • Market Cap $113.45M
  • PE -1
  • Debt $NaN
  • Cash $94.83M
  • EV $NaN
  • FCF -$86.06M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$94.11M
EBIT-$95.24M
ROE-65%
ROA-41%
FCF-$86.06M
Equity$144.12M
Growth Stability1
PE-1.21
PB0.79
P/FCF-1.32
P/S113.45
Price/Cash0.84
Net Margins-7K%
Op. Margins-10K%
Sales CAGR2%
Equity CAGR-3%
Earnings Growth YoY-17%
Earnings Growth QoQ47%
Sales CAGR 5Y2%
Equity CAGR 5Y-21%
Earnings CAGR 3Y-21%
Sales CAGR 3Y-21%
Equity CAGR 3Y-26%
Market Cap$113.45M
Revenue$1.00M
Assets$234.38M
Cash$94.83M
Shares Outstanding19.39M
Moat Score1%
Working Capital133.42M
Current Ratio5.82
Shares Growth 3y5%
Equity Growth QoQ-14%
Equity Growth YoY40%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single in-office intravitreal IVT injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust sustained treatment response reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor VEGF injections.

SEC Filings

Direct access to Adverum Biotechnologies, Inc. (ADVM) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Adverum Biotechnologies, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Adverum Biotechnologies, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Adverum Biotechnologies, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Adverum Biotechnologies, Inc..

= -$861M
012345678910TV
fcf-$86M-$86M-$86M-$86M-$86M-$86M-$86M-$86M-$86M-$86M-$86M-$861M
DCF-$78M-$71M-$65M-$59M-$53M-$49M-$44M-$40M-$36M-$33M-$332M
Value-$861M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-5K%-2K%-8K%-3K%-5K%-26K%--2K%--3K%-7K%
ROA--18%-49%-28%-35%-29%-24%-33%-50%-68%-41%
ROE--19%-53%-31%-36%-37%-27%-46%-85%-140%-65%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-----------
Debt over Equity-----------
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-305%-37%27%-13%-84%-100%--100%-2%
Earnings YoY growth-66%140%-51%29%-11%82%24%6%-24%-
Equity YoY growth-69%-15%-15%9%-13%148%-27%-43%-54%-21%
FCF YoY growth-482%6%14%18%25%33%35%-2%-24%-